Pasi Antero Janne
Brigham and Women's Hospital · 2,425 works · 128,138 citations · h-index 164
Top works
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- The landscape of somatic copy-number alteration across human cancers
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
- Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
- Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer